Halozyme Therapeutics Change in Accounts Receivable 2010-2025 | HALO
Halozyme Therapeutics change in accounts receivable for the twelve months ending March 31, 2025 was $-0.102B, a 407.93% decline year-over-year.
- Halozyme Therapeutics annual change in accounts receivable for 2024 was $-0.074B, a 2123.57% increase from 2023.
- Halozyme Therapeutics annual change in accounts receivable for 2023 was $-0.003B, a 96.02% decline from 2022.
- Halozyme Therapeutics annual change in accounts receivable for 2022 was $-0.084B, a 1342.65% decline from 2021.